Hospital
SMDC Medical Center
SMDC Medical Center was paid $35.51M by Medicaid between Jan 2018 and Dec 2024, across 212 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 77% of everything it billed.
33Billing provider infoSMDC MEDICAL CENTER
DULUTH, MN 55805
DULUTH, MN 55805
33aNPI1033153895assigned 06/15/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$35.51M
24GClaims621,905
24DCodes billed212
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Minnesota
Rank by total paid#6 of 36
Median peer was paid$11.46M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BOREN, KEVIN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 94,658 | $2.48M | |
| 2019 | 94,809 | $5.81M | |
| 2020 | 67,092 | $3.70M | |
| 2021 | 94,718 | $5.71M | |
| 2022 | 101,723 | $6.57M | |
| 2023 | 101,036 | $6.85M | |
| 2024incomplete | 67,869 | $4.37M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 77% | 394,463 | 350,714 | $27.35M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 10% | 15,664 | 1,853 | $3.66M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.9% | 7,710 | 7,563 | $688K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.4% | 1,159 | 563 | $480K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 7,518 | 6,902 | $473K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,951 | 1,876 | $253K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | <1% | 2,538 | 1,587 | $180K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 979 | 748 | $177K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,027 | 1,985 | $151K |
| 36415 | Collection of venous blood by venipuncture | <1% | 64,730 | 57,767 | $142K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,779 | 1,696 | $119K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,817 | 4,490 | $108K |
200 more codes
| 64615 | <1% | 539 | $105K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,485 | $88K |
| 97810 | <1% | 2,488 | $84K | |
| 97811 | <1% | 2,509 | $78K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 545 | $76K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 558 | $74K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 173 | $71K |
| 95117 | <1% | 2,540 | $57K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 774 | $51K |
| 97802 | <1% | 1,175 | $47K | |
| 20610 | <1% | 218 | $39K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 86 | $35K |
| Q3014 | Telehealth originating site facility fee | <1% | 4,693 | $34K |
| 80053 | Comprehensive metabolic panel | <1% | 7,150 | $32K |
| 90870 | <1% | 356 | $29K | |
| 92060 | <1% | 2,064 | $29K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,147 | $25K |
| 90686 | <1% | 2,184 | $24K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 133 | $24K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,289 | $24K |
| 92557 | <1% | 327 | $23K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,644 | $21K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,400 | $21K |
| 92567 | <1% | 2,535 | $20K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,032 | $20K |
| 80061 | Lipid panel | <1% | 1,996 | $20K |
| 93325 | <1% | 244 | $18K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 92 | $18K |
| 76536 | <1% | 258 | $18K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 499 | $17K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 208 | $17K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,836 | $17K |
| 97813 | <1% | 592 | $16K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,880 | $15K |
| 92587 | <1% | 66 | $15K | |
| 96116 | <1% | 144 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 768 | $14K |
| 97803 | <1% | 474 | $14K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,978 | $14K |
| 85027 | <1% | 6,370 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,883 | $12K |
| 0002A | <1% | 388 | $12K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 146 | $12K |
| H2012 | Behavioral health day treatment, per hour | <1% | 221 | $12K |
| 93320 | <1% | 162 | $11K | |
| 97814 | <1% | 604 | $11K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,123 | $11K |
| 91320 | <1% | 151 | $10K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,930 | $9K |
| 0001A | <1% | 353 | $9K | |
| 76830 | Ultrasound, transvaginal | <1% | 94 | $9K |
| 87631 | <1% | 149 | $8K | |
| 11721 | <1% | 687 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 323 | $8K |
| 96138 | <1% | 83 | $7K | |
| 77002 | <1% | 90 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 233 | $7K |
| 0072A | <1% | 211 | $6K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 70 | $6K |
| 97602 | <1% | 69 | $6K | |
| 62323 | <1% | 12 | $6K | |
| 90480 | <1% | 188 | $6K | |
| 0004A | <1% | 274 | $6K | |
| 0071A | <1% | 189 | $5K | |
| 73222 | <1% | 14 | $5K | |
| 71271 | <1% | 55 | $5K | |
| 0124A | <1% | 182 | $5K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 17 | $5K |
| 20611 | <1% | 15 | $4K | |
| 76881 | <1% | 40 | $4K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 51 | $4K |
| 76770 | <1% | 51 | $4K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 783 | $4K |
| 96367 | <1% | 61 | $4K | |
| 0240U | <1% | 29 | $3K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 997 | $3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 177 | $3K |
| 96139 | <1% | 101 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 39 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 681 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 203 | $3K |
| 95886 | <1% | 50 | $3K | |
| G0378 | Hospital observation service, per hour | <1% | 56 | $3K |
| 95908 | <1% | 12 | $2K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 13 | $2K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 16 | $2K |
| 90677 | <1% | 17 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 559 | $2K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 59 | $2K |
| 87632 | <1% | 20 | $2K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 383 | $2K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 26 | $2K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 32 | $2K |
| 0064A | <1% | 103 | $2K | |
| 96132 | <1% | 12 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 152 | $2K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 30 | $2K |
| 96118 | <1% | 42 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,529 | $2K |
| 80076 | <1% | 300 | $2K | |
| 95024 | <1% | 177 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15 | $1K |
| 97166 | <1% | 14 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 40 | $1K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,057 | $1K |
| 92579 | <1% | 26 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,080 | $1K |
| 92134 | <1% | 200 | $1K | |
| 76642 | <1% | 40 | $1K | |
| 96415 | <1% | 15 | $1K | |
| 86780 | <1% | 114 | $1K | |
| 0054A | <1% | 40 | $1K | |
| J0475 | Injection, baclofen, 10 mg | <1% | 16 | $1K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 60 | $1K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 31 | $1K |
| 82962 | <1% | 460 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,312 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 72 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 72 | $983.80 |
| 84439 | <1% | 92 | $980.23 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 475 | $950.98 |
| 85652 | <1% | 1,147 | $897.58 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,162 | $881.13 |
| 82565 | <1% | 946 | $846.61 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 92 | $829.11 |
| 95990 | <1% | 15 | $821.84 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $795.93 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,758 | $777.79 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 358 | $753.22 |
| 51798 | <1% | 111 | $729.67 | |
| 29075 | <1% | 19 | $687.23 | |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $678.91 |
| 76886 | <1% | 15 | $671.72 | |
| 71250 | <1% | 13 | $618.26 | |
| 81513 | <1% | 29 | $594.78 | |
| 84450 | <1% | 755 | $574.57 | |
| 85610 | <1% | 750 | $551.35 | |
| 96133 | <1% | 12 | $547.06 | |
| 82728 | <1% | 53 | $522.14 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,642 | $521.18 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,055 | $475.25 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,303 | $462.04 |
| 86803 | <1% | 56 | $442.09 | |
| 96119 | <1% | 13 | $442.04 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 13 | $423.46 |
| 0081A | <1% | 14 | $419.98 | |
| 87522 | Neg quan hep c or qual rna | <1% | 82 | $404.25 |
| 0011A | <1% | 89 | $370.68 | |
| 86706 | <1% | 40 | $327.49 | |
| 87510 | <1% | 95 | $308.14 | |
| 87340 | <1% | 52 | $288.85 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,441 | $266.53 |
| 87660 | <1% | 95 | $242.49 | |
| 87081 | <1% | 53 | $238.14 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 41 | $227.09 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 82 | $225.00 |
| 81001 | <1% | 53 | $221.60 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,690 | $205.27 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28 | $196.63 |
| 87480 | <1% | 95 | $190.98 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 21 | $188.42 |
| 86140 | <1% | 156 | $187.55 | |
| 84466 | <1% | 28 | $175.20 | |
| 96121 | <1% | 41 | $174.48 | |
| 80164 | <1% | 17 | $169.58 | |
| 85018 | <1% | 63 | $166.30 | |
| 82248 | <1% | 211 | $155.07 | |
| 36416 | <1% | 189 | $122.12 | |
| 83735 | <1% | 95 | $116.13 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 185 | $108.51 |
| 83655 | <1% | 12 | $105.84 | |
| 80069 | <1% | 14 | $92.83 | |
| 82140 | <1% | 40 | $89.26 | |
| 92133 | <1% | 12 | $85.45 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 38 | $83.79 |
| 90688 | <1% | 17 | $76.86 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 26 | $74.48 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 27 | $72.20 |
| 86364 | <1% | 24 | $70.44 | |
| 84703 | <1% | 19 | $63.36 | |
| 83540 | <1% | 28 | $59.04 | |
| 84460 | <1% | 60 | $53.73 | |
| 87481 | <1% | 29 | $53.41 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 29 | $53.41 |
| 84132 | <1% | 35 | $44.78 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 214 | $35.45 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 17 | $34.30 |
| 81003 | <1% | 54 | $31.94 | |
| 86762 | <1% | 12 | $21.42 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 251 | $12.39 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,550 | $0.01 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 21 | $0.01 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 75 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 18 | $0.00 |
| 90662 | 0% | 14 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 12 | $0.00 |
| 87634 | 0% | 23 | $0.00 | |
| 84100 | 0% | 17 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 175 | $0.00 |
| 80177 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOREN, KEVIN (CFO)
Parent organizationESSENTIA HEALTH
| Provider | Location | Paid |
|---|---|---|
| The Duluth Clinic, LTD | Duluth, MN | $51.60M |
| ST. Joseph's Medical Center | Brainerd, MN | $41.35M |
| ST Marys Medical Center | Duluth, MN | $20.98M |
| ST. Mary's Hospital of Superior | Superior, WI | $13.36M |
| ST Joseph's Medical Center | Baxter, MN | $7.23M |
| ST. Mary's Duluth Clinic Health System | Duluth, MN | $4.97M |
| Deer River Healthcare Center, INC. | Deer River, MN | $4.57M |
| ST. Mary's Medical Center | Duluth, MN | $3.66M |
| ST. Joseph's Medical Center | Brainerd, MN | $3.25M |
| The Duluth Clinic, LTD | Virginia, MN | $2.82M |
| The Duluth Clinic, LTD | Duluth, MN | $2.66M |
| Northern Pines Medical Center | Aurora, MN | $1.72M |
| ST. Mary's Hospital of Superior | Superior, WI | $1.65M |
| Polinsky Medical Rehabilitation Center | Duluth, MN | $1.61M |
| Pine Medical Center | Sandstone, MN | $1.32M |
| The Duluth Clinic, LTD | Hermantown, MN | $1.30M |
| The Duluth Clinic LTD | Grand Rapids, MN | $1.18M |
| The Duluth Clinic, LTD | Duluth, MN | $1.13M |
| The Duluth Clinic, LTD | Ashland, WI | $1.07M |
| ST Mary's Hospital of Superior | Spooner, WI | $1.05M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.